Moderator: Dr Anisa Mburu

1. Dr. Caroline Tonio – Advanced Endometrial Cancer

Dr. Tonio’s presentation highlighted significant advancements in the treatment of advanced and recurrent endometrial cancer. With rising incidence and poor outcomes in late-stage disease, treatment has evolved from conventional chemotherapy to biomarker-driven strategies.

Molecular subtyping, as identified by the TCGA, has enabled the use of immune checkpoint inhibitors (ICIs) and targeted therapies. Notably, ICIs like dostarlimab and pembrolizumab show strong efficacy in dMMR/MSI-H tumors. Emerging combinations of ICIs with chemotherapy or TKIs are improving survival outcomes. The integration of molecular profiling is now essential in selecting optimal therapies. Future care will increasingly rely on predictive biomarkers to guide personalized treatment.

2. Dr. Khadija Warfa – Endometrial Cancer Pathology and Surgical Staging

Dr. Warfa provided an overview of the pathology, risk factors, and staging of endometrial cancer. Most cases occur in postmenopausal women, with abnormal bleeding as a common symptom. Risk factors include estrogen exposure, obesity, and genetic syndromes.

Diagnosis relies on biopsy and imaging. Pathologically, cancers are divided into Type I and II, with molecular subtypes (e.g., POLE, dMMR, p53-abn) offering greater prognostic value.

Standard surgical management involves hysterectomy with lymph node assessment. Sentinel lymph node biopsy is preferred in many cases due to lower complication rates. Minimally invasive approaches offer comparable survival outcomes with reduced morbidity.